[go: up one dir, main page]

MX2012007875A - Uso de derivados de 5-[[2, 3-dimetil-2h-indazol-6-il)-metilamino]- 2-pirimidil] amino]-2-metilbencensulfonamida en transtornos oculares. - Google Patents

Uso de derivados de 5-[[2, 3-dimetil-2h-indazol-6-il)-metilamino]- 2-pirimidil] amino]-2-metilbencensulfonamida en transtornos oculares.

Info

Publication number
MX2012007875A
MX2012007875A MX2012007875A MX2012007875A MX2012007875A MX 2012007875 A MX2012007875 A MX 2012007875A MX 2012007875 A MX2012007875 A MX 2012007875A MX 2012007875 A MX2012007875 A MX 2012007875A MX 2012007875 A MX2012007875 A MX 2012007875A
Authority
MX
Mexico
Prior art keywords
treatment method
hydrates
administration
patient
directed
Prior art date
Application number
MX2012007875A
Other languages
English (en)
Inventor
Valeriu Damian-Iordache
Andrew King
Megan M Mclaughli
Albert B Suttle
Original Assignee
Glaxo Wellcome Mfg Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Wellcome Mfg Pte Ltd filed Critical Glaxo Wellcome Mfg Pte Ltd
Publication of MX2012007875A publication Critical patent/MX2012007875A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a métodos para el tratamiento de trastornos de angiogénesis ocular o filtración vascular en un paciente, mediante la administración de inhibidores adecuados, incluyendo pazopanib o sales farmacéuticamente aceptables o hidratos del mismo.
MX2012007875A 2010-01-06 2011-01-05 Uso de derivados de 5-[[2, 3-dimetil-2h-indazol-6-il)-metilamino]- 2-pirimidil] amino]-2-metilbencensulfonamida en transtornos oculares. MX2012007875A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29274710P 2010-01-06 2010-01-06
PCT/US2011/020231 WO2011085007A1 (en) 2010-01-06 2011-01-05 Treatment method

Publications (1)

Publication Number Publication Date
MX2012007875A true MX2012007875A (es) 2012-08-03

Family

ID=44305773

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012007875A MX2012007875A (es) 2010-01-06 2011-01-05 Uso de derivados de 5-[[2, 3-dimetil-2h-indazol-6-il)-metilamino]- 2-pirimidil] amino]-2-metilbencensulfonamida en transtornos oculares.

Country Status (21)

Country Link
US (1) US20130012531A1 (es)
EP (1) EP2521550A4 (es)
JP (1) JP2013516472A (es)
KR (1) KR20120125244A (es)
CN (1) CN102781450A (es)
AU (1) AU2011203706A1 (es)
BR (1) BR112012016673A2 (es)
CA (1) CA2786328A1 (es)
CL (1) CL2012001852A1 (es)
CO (1) CO6561789A2 (es)
DO (1) DOP2012000174A (es)
EA (1) EA201290603A1 (es)
IL (1) IL220594A0 (es)
MA (1) MA33991B1 (es)
MX (1) MX2012007875A (es)
PE (1) PE20121523A1 (es)
PH (1) PH12012501358A1 (es)
SG (1) SG181826A1 (es)
TW (1) TW201201808A (es)
UY (1) UY33164A (es)
WO (1) WO2011085007A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10166142B2 (en) 2010-01-29 2019-01-01 Forsight Vision4, Inc. Small molecule delivery with implantable therapeutic device
TW201206908A (en) * 2010-05-05 2012-02-16 Glaxo Wellcome Mfg Pte Ltd Pharmaceutical compositions and methods of making same
EP2640360A2 (en) 2010-11-19 2013-09-25 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
AU2013255050B2 (en) * 2012-05-01 2016-07-28 Translatum Medicus Inc. Methods for treating and diagnosing blinding eye diseases
AU2014236455B2 (en) 2013-03-14 2018-07-12 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
US11136625B2 (en) 2013-08-28 2021-10-05 Crown Bioscience, Inc. (Taicang) Gene expression signatures predictive of subject response to a multi-kinase inhibitor and methods of using the same
CA2957548A1 (en) 2014-08-08 2016-02-11 Forsight Vision4, Inc. Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof
WO2016200688A1 (en) * 2015-06-06 2016-12-15 Cloudbreak Therapeutics, Llc Compositions and methods for treating pterygium
US10323349B2 (en) * 2015-09-25 2019-06-18 Kyoudojyutaku Co., Ltd. Washing system
KR102408596B1 (ko) 2016-06-02 2022-06-13 에이디에스 테라퓨틱스 엘엘씨 비정상적 신생혈관이 있는 안구 질환 치료를 위한, 닌테다닙을 사용하는 조성물 및 방법
CA3144861A1 (en) 2019-06-25 2020-12-30 Translatum Medicus, Inc. Processes of making 2-((1-benzyl-1h-indazol-3-yl)methoxy)-2-methylpropanoic acid and its derivatives

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1343782B1 (en) * 2000-12-21 2009-05-06 SmithKline Beecham Corporation Pyrimidineamines as angiogenesis modulators
US20080293691A1 (en) * 2005-11-29 2008-11-27 Smithkline Beecham Corporation Treatment Method
US20090004213A1 (en) * 2007-03-26 2009-01-01 Immatics Biotechnologies Gmbh Combination therapy using active immunotherapy
US8334239B2 (en) * 2007-07-10 2012-12-18 The Board Of Regents Of The University Of Texas System High affinity VEGF-receptor antagonists
US20090325959A1 (en) * 2008-06-26 2009-12-31 Vittitow Jason L Method for treating ophthalmic diseases using rho kinase inhibitor compounds
JP2012533562A (ja) * 2009-07-16 2012-12-27 グラクソ ウェルカム マニュファクチュアリング ピーティーイー リミテッド 治療法

Also Published As

Publication number Publication date
UY33164A (es) 2011-08-31
SG181826A1 (en) 2012-07-30
US20130012531A1 (en) 2013-01-10
CL2012001852A1 (es) 2012-11-30
CO6561789A2 (es) 2012-11-15
DOP2012000174A (es) 2012-12-15
IL220594A0 (en) 2012-08-30
KR20120125244A (ko) 2012-11-14
WO2011085007A1 (en) 2011-07-14
EA201290603A1 (ru) 2013-03-29
TW201201808A (en) 2012-01-16
CN102781450A (zh) 2012-11-14
BR112012016673A2 (pt) 2018-06-05
CA2786328A1 (en) 2011-07-14
PE20121523A1 (es) 2012-12-12
JP2013516472A (ja) 2013-05-13
EP2521550A4 (en) 2013-07-03
EP2521550A1 (en) 2012-11-14
PH12012501358A1 (en) 2019-03-22
MA33991B1 (fr) 2013-02-01
AU2011203706A1 (en) 2012-07-12

Similar Documents

Publication Publication Date Title
PH12012501358A1 (en) Treatment method
MX363243B (es) Composiciones para tratar cáncer y usos de dichas composiciones.
MD4539B1 (ro) 4-Fenilpiridine substituite pentru tratamentul bolilor asociate cu receptorul NK-1
EP4233869A3 (en) Use of pyrazolopyrimidine derivatives for the treatment of pi3k related disorders
PH12016502355B1 (en) Pharmaceutical composition
MY191100A (en) Treatment for lipodystrophy
EA201190337A1 (ru) Способ лечения
SG195257A1 (en) Anti-thrombotic compounds
MX2013008340A (es) Novedosas 4-amino-n-hidroxi-benzamidas para el tratamiento de cancer.
MX348723B (es) Combinaciones de solifenacina y estimulantes salivales para el tratamiento de la vejiga hiperactiva.
WO2011133826A3 (en) Method for treating pancreatic cancer
MX2021014120A (es) Tratamiento de los sintomas asociados a terapia privacion de androgenos.
PH12015501211A1 (en) Use of pidotimod to treat atopic dermatitis
MX2014000870A (es) Composiciones farmaceuticas que comprenden 4-bromo-n-(imidazolidin -2-iliden)-1h-benzimidazol-5-amina para tratar enfermedades de la retina.
GB201107576D0 (en) Novel compounds and methods for use in medicine
UA56440U (ru) Способ лечения бактериального хронического одонтогенного остеомиелита челюсти
UA55818U (ru) Способ лечения хронических заболеваний роговицы
UA68841U (ru) Способ хирургического лечения варикоцеле
MY165030A (en) Treatment of seborrhoea
NZ623275A (en) Treatment of ocular disease
UA69982U (ru) Способ лечения рецидивирующей формы герпетической инфекции
UA69624U (uk) Спосіб профілактики загострення хронічного бронхіту у хворих зі сполученим перебігом з пептичною виразкою дванадцятипалої кишки
UA66494U (ru) Способ лечения холедохолитиаза
UA74055U (ru) Способ хирургического лечения рефрактерных форм глаукомы
UA67427U (ru) Способ лечения фиброзно-кавернозных форм органного туберкулеза

Legal Events

Date Code Title Description
FA Abandonment or withdrawal